Well-matched unrelated donor hematopoietic cell transplantation (HCT) yields comparable outcomes compared to matched related donor HCT in patients with MDS, according to a study of 701 adult MDS patients transplanted between 2002 and 2006 and reported to CIBMTR (Center for International Blood and Marrow Transplant Research). Median patient age was 53 years (range, 22-78), and 31% had Karnofsky performance scores <90% at time of transplant. Three-year survival for matched related transplants and 8/8 HLA-matched unrelated donor transplants were 44% and 39%, respectively (p=0.27). Three-year survival using 7/8 matched unrelated donors was 29%, significantly lower than matched related donors (p=0.01).
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Related, Well-Matched Unrelated HCT Outcomes Comparable in MDS
Jul 2013